drugset / Trial / NCT04481282
The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
NaSingle-groupOpen-labelTreatment
Summary
Single-arm, open-label, single center study to assess the efficacy and safety of terbutaline plus danazol in patients with corticosteroid resistant/relapsed ITP.
Timeline
- Start
- 2020-07-08
- Primary completion
- 2021-03-31
- Completion
- 2021-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danazol | Other / unclassified | 200 mg | Oral |
| Subject | Terbutaline | Small molecule | 2.5 mg | Oral |